New York, NYNCT03213002Now EnrollingIRB Ready

Glioblastoma Multiforme (GBM) Clinical Trial in New York, NY

Access cutting-edge glioblastoma multiforme (gbm) treatment through this phase 1/2 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Northwell Health

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access glioblastoma multiforme (gbm) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma multiforme (gbm) treatment provided free

Apply for This New York Location

Check if you qualify for this glioblastoma multiforme (gbm) clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Glioblastoma Multiforme (GBM) Study in New York

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.

Sponsor: Northwell Health

Who Can Participate

Inclusion Criteria

Be capable of giving informed consent.
Have a pathology proven diagnosis of any of newly diagnosed Glioblastoma Multiforme WHO IV
Have completed the first part of standard of care chemo-radiation (Stupp), for 6 weeks, and not started the maintenance phase of temozolomide
Agree to use effective barrier contraception while on treatment and for 2 months thereafter, if of childbearing potential
Have a life expectancy \> 3 months
Be between the ages of 18 to 74
Have a performance status KPS 70 or greater
Be able to swallow pills and capsules
Be able to tolerate oral chemotherapeutic medications, with no health threatening allergies or side effects, based on lab and clinical findings
Have adequate bone marrow function, liver function and renal function before commencing therapy

Exclusion Criteria

Prior chemotherapy with capecitabine or temozolomide for other prior malignancies. Patients previously treated with continuous infusion 5-FU or any schedule of DTIC, which are similar to capecitabine and temozolomide, respectively, will be excluded.
Prior chemotherapies for newly diagnosed GBM or AA, other than temozolomide during radiation.
Patients with a history of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide (i.e. anaphylaxis or anaphylactic reactions),
Serious medical or psychiatric illness preventing informed consent or treatment (e.g., serious infection)
Prior malignancies in the last 5 years other than curatively treated carcinoma in-situ previously treated with curative intent (cancer free for the past one year).
Performance status, KPS \< 70
Inability to swallow pills and capsules
Concurrent chemotherapy or treatment for the active disease, including devices such as Optune, high dose vitamin supplements, or any other chemotherapy
Patients taking concomitant medications such as Coumadin and phenytoin medications, need to be excluded because of interactions with capecitabine
Patients with previously documented CAD will need to be evaluated by cardiology prior to start to help risk stratify for capecitabine tolerance
Patients with renal insufficiency or hepatic insufficiency
Patients with coagulopathies
Women who are pregnant or lactating.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT03213002) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Multiforme (GBM) Treatment Options in New York, NY

If you're searching for glioblastoma multiforme (gbm) treatment options in New York, NY, this clinical trial (NCT03213002) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced glioblastoma multiforme (gbm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma multiforme (gbm) clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in New York, NY

See all brain cancer clinical trials recruiting in New York — not just this study.

Browse Brain Cancer Trials in New York →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY